Core Current Deferred Revenue vs Capex To Revenue Analysis

CORZZ Stock

14.10 0.29 2.02%

Core Scientific, financial indicator trend analysis is way more than just evaluating Core Scientific, Tranche prevailing accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Core Scientific, Tranche is a good investment. Please check the relationship between Core Scientific, Current Deferred Revenue and its Capex To Revenue accounts. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Core Scientific, Tranche. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in nation.

Current Deferred Revenue vs Capex To Revenue

Current Deferred Revenue vs Capex To Revenue Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Core Scientific, Tranche Current Deferred Revenue account and Capex To Revenue. At this time, the significance of the direction appears to have weak contrarian relationship.

The correlation between Core Scientific,'s Current Deferred Revenue and Capex To Revenue is -0.03. Overlapping area represents the amount of variation of Current Deferred Revenue that can explain the historical movement of Capex To Revenue in the same time period over historical financial statements of Core Scientific, Tranche, assuming nothing else is changed. The correlation between historical values of Core Scientific,'s Current Deferred Revenue and Capex To Revenue is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Current Deferred Revenue of Core Scientific, Tranche are associated (or correlated) with its Capex To Revenue. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Capex To Revenue has no effect on the direction of Current Deferred Revenue i.e., Core Scientific,'s Current Deferred Revenue and Capex To Revenue go up and down completely randomly.

Correlation Coefficient

-0.03

Relationship Direction	Negative
Relationship Strength	Insignificant

View All Relationships

Current Deferred Revenue

Revenue that has been collected but not yet earned, typically from prepaid service contracts or subscriptions. This amount is considered a liability until the service is provided or the subscription period ends.

Capex To Revenue

The ratio of a company's capital expenditures to its total revenue, indicating how much of the revenue is used for acquiring or maintaining physical assets.

Most indicators from Core Scientific,'s fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Core Scientific, Tranche current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Core Scientific, Tranche. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in nation.

At this time, Core Scientific,'s Tax Provision is fairly stable compared to the past year. Selling General Administrative is likely to rise to about 108.6 M in 2024, whereas Sales General And Administrative To Revenue is likely to drop 0.18 in 2024.

	2021	2023	2024 (projected)
Interest Expense	96.8M	99.2M	63.8M
Depreciation And Amortization	96.4M	110.9M	116.5M

Interest Expense Depreciation And Amortization

Core Scientific, fundamental ratios Correlations

	Long Term Debt	Good Will	Intangible Assets	Total Assets	Short Long Term Debt Total	Other Current Liab	Total Current Liabilities	Total Stockholder Equity	Property Plant And Equipment Net	Current Deferred Revenue	Net Debt	Retained Earnings	Accounts Payable	Cash	Non Current Assets Total	Non Currrent Assets Other	Cash And Short Term Investments	Net Receivables	Common Stock Shares Outstanding	Non Current Liabilities Total	Capital Lease Obligations	Inventory	Other Current Assets	Other Stockholder Equity	Total Liab	Net Invested Capital
Long Term Debt		0.22	-0.23	0.67	0.97	0.67	0.88	-0.29	0.98	-0.2	0.87	-0.87	0.85	0.73	0.82	0.93	0.83	0.75	0.96	0.97	0.78	-0.99	0.24	0.96	0.98	0.26
Good Will	0.22		0.76	0.87	0.27	-0.13	0.16	0.86	0.25	0.91	0.24	0.27	-0.21	0.79	0.74	0.39	0.72	-0.15	0.07	0.19	0.61	-0.29	1.0	0.15	0.19	0.97
Intangible Assets	-0.23	0.76		0.45	-0.25	-0.29	-0.27	0.87	-0.26	0.87	-0.09	0.63	-0.48	0.39	0.29	-0.08	0.27	-0.35	-0.42	-0.31	0.21	0.2	0.76	-0.36	-0.31	0.75
Total Assets	0.67	0.87	0.45		0.69	0.2	0.54	0.51	0.69	0.58	0.59	-0.24	0.25	0.95	0.97	0.74	0.96	0.23	0.53	0.64	0.83	-0.72	0.87	0.59	0.63	0.85
Short Long Term Debt Total	0.97	0.27	-0.25	0.69		0.58	0.91	-0.24	0.99	-0.15	0.81	-0.84	0.77	0.73	0.81	0.95	0.83	0.66	0.98	0.99	0.79	-0.98	0.28	0.99	1.0	0.29
Other Current Liab	0.67	-0.13	-0.29	0.2	0.58		0.8	-0.5	0.55	-0.41	0.91	-0.68	0.92	0.46	0.37	0.71	0.42	0.99	0.63	0.54	0.65	-0.6	-0.08	0.59	0.64	0.07
Total Current Liabilities	0.88	0.16	-0.27	0.54	0.91	0.8		-0.32	0.86	-0.21	0.91	-0.8	0.86	0.7	0.67	0.96	0.7	0.84	0.91	0.86	0.86	-0.87	0.2	0.91	0.93	0.28
Total Stockholder Equity	-0.29	0.86	0.87	0.51	-0.24	-0.5	-0.32		-0.26	0.99	-0.23	0.71	-0.65	0.38	0.31	-0.11	0.28	-0.55	-0.43	-0.31	0.18	0.23	0.85	-0.35	-0.32	0.8
Property Plant And Equipment Net	0.98	0.25	-0.26	0.69	0.99	0.55	0.86	-0.26		-0.17	0.78	-0.85	0.77	0.71	0.82	0.92	0.83	0.64	0.97	1.0	0.75	-0.99	0.26	0.98	0.99	0.25
Current Deferred Revenue	-0.2	0.91	0.87	0.58	-0.15	-0.41	-0.21	0.99	-0.17		-0.12	0.64	-0.56	0.48	0.39	0.0	0.37	-0.46	-0.34	-0.23	0.29	0.14	0.9	-0.26	-0.23	0.87
Net Debt	0.87	0.24	-0.09	0.59	0.81	0.91	0.91	-0.23	0.78	-0.12		-0.71	0.89	0.78	0.72	0.92	0.76	0.92	0.79	0.76	0.89	-0.84	0.28	0.78	0.83	0.39
Retained Earnings	-0.87	0.27	0.63	-0.24	-0.84	-0.68	-0.8	0.71	-0.85	0.64	-0.71		-0.91	-0.32	-0.43	-0.73	-0.46	-0.77	-0.93	-0.88	-0.46	0.84	0.25	-0.89	-0.88	0.22
Accounts Payable	0.85	-0.21	-0.48	0.25	0.77	0.92	0.86	-0.65	0.77	-0.56	0.89	-0.91		0.44	0.45	0.78	0.49	0.97	0.85	0.77	0.61	-0.79	-0.17	0.8	0.83	-0.07
Cash	0.73	0.79	0.39	0.95	0.73	0.46	0.7	0.38	0.71	0.48	0.78	-0.32	0.44		0.96	0.86	0.97	0.47	0.6	0.66	0.95	-0.76	0.81	0.65	0.7	0.84
Non Current Assets Total	0.82	0.74	0.29	0.97	0.81	0.37	0.67	0.31	0.82	0.39	0.72	-0.43	0.45	0.96		0.85	1.0	0.41	0.69	0.78	0.87	-0.85	0.74	0.73	0.77	0.74
Non Currrent Assets Other	0.93	0.39	-0.08	0.74	0.95	0.71	0.96	-0.11	0.92	0.0	0.92	-0.73	0.78	0.86	0.85		0.87	0.75	0.9	0.9	0.94	-0.93	0.42	0.92	0.94	0.48
Cash And Short Term Investments	0.83	0.72	0.27	0.96	0.83	0.42	0.7	0.28	0.83	0.37	0.76	-0.46	0.49	0.97	1.0	0.87		0.46	0.7	0.79	0.9	-0.86	0.73	0.75	0.79	0.73
Net Receivables	0.75	-0.15	-0.35	0.23	0.66	0.99	0.84	-0.55	0.64	-0.46	0.92	-0.77	0.97	0.47	0.41	0.75	0.46		0.72	0.63	0.66	-0.68	-0.11	0.68	0.72	0.03
Common Stock Shares Outstanding	0.96	0.07	-0.42	0.53	0.98	0.63	0.91	-0.43	0.97	-0.34	0.79	-0.93	0.85	0.6	0.69	0.9	0.7	0.72		0.98	0.7	-0.96	0.08	1.0	0.99	0.1
Non Current Liabilities Total	0.97	0.19	-0.31	0.64	0.99	0.54	0.86	-0.31	1.0	-0.23	0.76	-0.88	0.77	0.66	0.78	0.9	0.79	0.63	0.98		0.71	-0.98	0.2	0.99	0.99	0.19
Capital Lease Obligations	0.78	0.61	0.21	0.83	0.79	0.65	0.86	0.18	0.75	0.29	0.89	-0.46	0.61	0.95	0.87	0.94	0.9	0.66	0.7	0.71		-0.79	0.65	0.73	0.78	0.72
Inventory	-0.99	-0.29	0.2	-0.72	-0.98	-0.6	-0.87	0.23	-0.99	0.14	-0.84	0.84	-0.79	-0.76	-0.85	-0.93	-0.86	-0.68	-0.96	-0.98	-0.79		-0.3	-0.97	-0.98	-0.31
Other Current Assets	0.24	1.0	0.76	0.87	0.28	-0.08	0.2	0.85	0.26	0.9	0.28	0.25	-0.17	0.81	0.74	0.42	0.73	-0.11	0.08	0.2	0.65	-0.3		0.16	0.2	0.98
Other Stockholder Equity	0.96	0.15	-0.36	0.59	0.99	0.59	0.91	-0.35	0.98	-0.26	0.78	-0.89	0.8	0.65	0.73	0.92	0.75	0.68	1.0	0.99	0.73	-0.97	0.16		1.0	0.17
Total Liab	0.98	0.19	-0.31	0.63	1.0	0.64	0.93	-0.32	0.99	-0.23	0.83	-0.88	0.83	0.7	0.77	0.94	0.79	0.72	0.99	0.99	0.78	-0.98	0.2	1.0		0.22
Net Invested Capital	0.26	0.97	0.75	0.85	0.29	0.07	0.28	0.8	0.25	0.87	0.39	0.22	-0.07	0.84	0.74	0.48	0.73	0.03	0.1	0.19	0.72	-0.31	0.98	0.17	0.22

Click cells to compare fundamentals

Core Scientific, Account Relationship Matchups

Core Scientific, fundamental ratios Accounts

		2019	2020	2021	2022	2023	2024 (projected)
Intangible Assets		6.7M	8.2M	1.7M	2.2M	2.0M	3.6M

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

C	Citigroup
GM	General Motors
F	Ford Motor

Additional Tools for Core Stock Analysis

When running Core Scientific,'s price analysis, check to measure Core Scientific,'s market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Core Scientific, is operating at the current time. Most of Core Scientific,'s value examination focuses on studying past and present price action to predict the probability of Core Scientific,'s future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Core Scientific,'s price. Additionally, you may evaluate how the addition of Core Scientific, to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Core Current Deferred Revenue vs Capex To Revenue Analysis

Current Deferred Revenue vs Capex To Revenue

Current Deferred Revenue vs Capex To Revenue Correlation Analysis

Correlation Coefficient

Current Deferred Revenue

Capex To Revenue

Core Scientific, fundamental ratios Correlations

Core Scientific, Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Core Scientific, fundamental ratios Accounts

Also Currently Popular

Additional Tools for Core Stock Analysis

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Other Current Assets	+ 1.0	Good Will
Total Liab	+ 1.0	Short Long Term Debt Total
Non Current Liabilities Total	+ 1.0	Property Plant And Equipment Net
Cash And Short Term Investments	+ 1.0	Non Current Assets Total
Other Stockholder Equity	+ 1.0	Common Stock Shares Outstanding
Total Liab	+ 1.0	Other Stockholder Equity

Inventory	- 0.99	Property Plant And Equipment Net
Inventory	- 0.99	Long Term Debt
Total Liab	- 0.98	Inventory
Inventory	- 0.98	Non Current Liabilities Total
Inventory	- 0.98	Short Long Term Debt Total
Other Stockholder Equity	- 0.97	Inventory